2iq9: Difference between revisions

Revision as of 21:17, 27 July 2008

This article has been automatically seeded. Changes to this page should pertain to the PDB entry only and not to the protein or biomolecule in general.

File:2iq9.png

Template:STRUCTURE 2iq9

PFA2 FAB fragment, triclinic apo formPFA2 FAB fragment, triclinic apo form

Template:ABSTRACT PUBMED 17895381

About this StructureAbout this Structure

Full crystallographic information is available from OCA.

ReferenceReference

Molecular basis for passive immunotherapy of Alzheimer's disease., Gardberg AS, Dice LT, Ou S, Rich RL, Helmbrecht E, Ko J, Wetzel R, Myszka DG, Patterson PH, Dealwis C, Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15659-64. Epub 2007 Sep 25. PMID:17895381

Page seeded by OCA on Sun Jul 27 21:17:39 2008

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 1: / Line 1: @@
-[[Image:2iq9.jpg|left|200px]]
+{{Seed}}
+[[Image:2iq9.png|left|200px]]
 <!--
@@ Line 9: / Line 10: @@
 {{STRUCTURE_2iq9|  PDB=2iq9  |  SCENE=  }}
-'''PFA2 FAB fragment, triclinic apo form'''
+===PFA2 FAB fragment, triclinic apo form===
-==Overview==
+<!--
-Amyloid aggregates of the amyloid-beta (Abeta) peptide are implicated in the pathology of Alzheimer's disease. Anti-Abeta monoclonal antibodies (mAbs) have been shown to reduce amyloid plaques in vitro and in animal studies. Consequently, passive immunization is being considered for treating Alzheimer's, and anti-Abeta mAbs are now in phase II trials. We report the isolation of two mAbs (PFA1 and PFA2) that recognize Abeta monomers, protofibrils, and fibrils and the structures of their antigen binding fragments (Fabs) in complex with the Abeta(1-8) peptide DAEFRHDS. The immunodominant EFRHD sequence forms salt bridges, hydrogen bonds, and hydrophobic contacts, including interactions with a striking WWDDD motif of the antigen binding fragments. We also show that a similar sequence (AKFRHD) derived from the human protein GRIP1 is able to cross-react with both PFA1 and PFA2 and, when cocrystallized with PFA1, binds in an identical conformation to Abeta(1-8). Because such cross-reactivity has implications for potential side effects of immunotherapy, our structures provide a template for designing derivative mAbs that target Abeta with improved specificity and higher affinity.
+The line below this paragraph, {{ABSTRACT_PUBMED_17895381}}, adds the Publication Abstract to the page
+(as it appears on PubMed at http://www.pubmed.gov), where 17895381 is the PubMed ID number.
+-->
+{{ABSTRACT_PUBMED_17895381}}
 ==About this Structure==
@@ Line 26: / Line 30: @@
 [[Category: Pfa2]]
 [[Category: Wwddd]]
-''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May  4 07:46:11 2008''
+''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Jul 27 21:17:39 2008''